Dr Reddy’s Ready for Growth As Imports Surge After Quiet Quarter — Panjiva
Más

Panjiva_research_logo

Dr Reddy’s Ready for Growth As Imports Surge After Quiet Quarter

Health Care 108 U.S. 3297

Generic pharmaceuticals manufacturer Dr. Reddy’s Labs reported third quarter revenues that expanded by 7.1% year over year despite U.S. revenues that were down by 0.3% in reporting currency terms, S&P Global Market Intelligence data shows. The decline in U.S. revenues was the result in part of lower pricing.

That’s been a common factor for exporters of pharmaceuticals to America with a 13.6% fall in average import values per gram (AIVG) in the three months to Aug. 31 on a year earlier, as outlined in Panjiva research of Oct. 29.

CFO Saumen Chakraborty also blamed the slowdown on the lack of volumes of generic Suboxone (buprenorphine, an opioid treatment) due to a patent dispute.

DRUGS GETTING CHEAPER ON ARRIVAL

Chart shows average import value per gram for all packaged pharmaceuticals coming into the United States on a monthly (bar) and trailing annual average (solid) basis.   Source: Panjiva

Yet, there may be room for a significant upturn in the coming two quarters. The company has four product releases during October, according to an Economic Times interview with Mr. Chakraborty.

Panjiva data shows a marked rebound in Dr. Reddy’s seaborne imports to the U.S. with a 117% surge in September and October vs. a year earlier on a preliminary basis. The actual delivery of sales on an ongoing basis, however, will depend on the company gaining FDA approval to reopen two of its factories

REDDY’S REBOUND COMES AHEAD OF OCTOBER PRODUCT LAUNCHES

Chart shows U.S. seaborne imports associated with Dr. Reddy’s.   Source: Panjiva

The rapid growth seen by Dr. Reddy’s is not unusual across the generic pharmaceutical suppliers. Indeed total seaborne shipments across 13 large pharma companies increased by 52.8% on a year earlier in the third quarter, led by a 72.7% from Aurobindo, the largest supplier by volume. Not all manufacturers are being as aggressive, however, with decreased shipments from Teva (down 16.0%), Amneal (14.8% lower) and Cipla (off 19.5%).

TEVA IN A PROLONGED DOWNTURN AS REDDY’S RECOVERS

Chart segments U.S. seaborne imports by shipper name.   Source: Panjiva

PANJIVA RESEARCH is a service provided by Panjiva, Inc. ("Panjiva") to relevant global subscribers, and are deemed to be Panjiva "Services" subject to the Panjiva Terms & Conditions of Use. Information contained within or made available via the Services is for informational purposes only and nothing in the Services shall constitute or be construed as an offering of financial instruments, or as investment advice or recommendations by Panjiva, Inc. or its affiliates of an investment strategy or whether to "buy", "sell" or "hold" an investment. The Services may include views and commentary about customers of Panjiva. No aspect of the Services is based on consideration of your individual circumstances, and you should determine on your own whether you agree with the information contained within or made available via the Services. Employees involved in Panjiva Research may hold positions in securities analyzed or discussed in the Services. Panjiva does not make any express or implied warranties, representations, endorsements or conditions with respect to the Services and the information contained within or made available via the Services, including without limitation, warranties as to the usefulness, completeness, accuracy, currentness, reliability or sufficiency of any information (including, without limitation, conclusions, statements, opinions, estimates, forecasts or projections of any kind) and expressly disclaims any implied warranties. Neither this disclaimer nor any of its contents may be forwarded or redistributed without the prior written consent of Panjiva. © 2019 Panjiva, Inc. All Rights Reserved.